



Sangamo BioSciences to Present at the William Blair & Company 23rd Annual Growth Stock Conference

RICHMOND, Calif., June 25 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that Edward Lanphier, the company's president and chief executive officer, will present at the William Blair & Company 23rd Annual Growth Stock Conference in Chicago on Thursday, June 26 at 9:40 am Central Time. The audio presentation will be webcast live and a replay of the presentation will be available for 60 days after the conference; both can be accessed via the following link <http://www.twst.com/econf/mm/blair2/sgmo.html> .

About Sangamo

Sangamo BioSciences, Inc., of Richmond, CA, is focused on the research and development of novel transcription factors for the regulation of gene expression. The company's most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Other therapeutics development programs are focused on cancer, neuropathic pain, ophthalmic and infectious diseases. Sangamo's proprietary technology enables the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins, or ZFPs. By engineering ZFPs so that they can recognize a specific gene and fusing this to a suitable functional domain, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics and pharmaceutical discovery. Sangamo is also developing ZFP-restriction enzymes for use in targeted gene correction for the treatment and potential cure of monogenic disease. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and applications of Sangamo's ZFP Therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.

CONTACT:

Elizabeth Wolffe, Ph.D., of Sangamo BioSciences, Inc.,
+1-510-970-6000, ext., 271,
or ewolffe@sangamo.com
Web site: <http://www.twst.com/econf/mm/blair2/sgmo.html>
Web site: <http://www.sangamo.com>